RAD-302

N/A

Report date: 2025/11/20 16:05:05

Base Information

Drug NameRAD-302
Drug Alias NameRAD-302177Lu-RAD-302
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIntegrin alpha-V/beta-6 antagonists
TargetsIntegrin alpha-V/beta-6
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRadiopharm Theranostics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A